Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis.

Add to Collection

2014 Jan Others SG Vankar, P Dutta, HS Kohli… - … Indian Journal of Medical …, 2014 - ncbi.nlm.nih.gov 83

Full Author : ['Vankar, Sameer G', 'Dutta, Pinaki', 'Kohli, H S', 'Bhansali, Anil']
Journal Title : The Indian journal of medical research
Chapter : Section3
Journal Year : 2014
Cited by : 7.0

BACKGROUND & OBJECTIVES: Chronic kidney disease (CKD) patients on dialysis regularly receive erythropoiesis stimulating agent (ESA) for treating renal anaemia during their dialysis unlike those who are not on dialysis. In such patients, the longer acting ..... Read More

Keywords : ["continuous erythropoietin receptor activator cera", "treat renal anaemia", "chronic kidney disease", "efficacy safety", "diabetic patient", "dialysis"]
PubMed Link : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994727/
Google Scholar Link : https://scholar.google.com/scholar?cites=17820105700177962309&as_sdt=5,44&sciodt=0,44&hl=en&num=20

Have a Question?

Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis.